Methods: Implementation of<i>in vitro</i>and<i>ex vivo</i>phagocytosis and respiratory burst function assessments in safety testing
Wendy Freebern(Bristol-Myers Squibb (Germany)), Helen G. Haggerty(Bristol-Myers Squibb (Germany)), Tammy Bigwarfe(Boehringer Ingelheim (United States)), Karen Price(Purchase College)
Cited by 12
Related Papers
Rational Development of LEA29Y (belatacept), a High-Affinity Variant of CTLA4-Ig with Potent Immunosuppressive Properties
|American Journal of Transplantation|2005|714
Cancer Drug Discovery and Development
|Humana Press eBooks|2003|194
Development of a Chimeric Anti-CD40 Monoclonal Antibody That Synergizes with LEA29Y to Prolong Islet Allograft Survival
|The Journal of Immunology|2005|183
Fc-Silent Anti-CD154 Domain Antibody Effectively Prevents Nonhuman Primate Renal Allograft Rejection
|American Journal of Transplantation|2017|96